04th week of 2017 patent applcation highlights part 9 |
Patent application number | Title | Published |
20170020862 | INTRANASAL NALTREXONE - A stable transmucosal composition consisting essentially of naltrexone hydrochloride in water is provided. The composition is surprisingly stable at room temperature and can be used for simple, rapid and effective opioid overdose rescue. | 2017-01-26 |
20170020863 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2017-01-26 |
20170020864 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2017-01-26 |
20170020866 | TREATMENT OF PARKINSON'S DISEASE THROUGH ARFGAP1 INHIBITION USING SUBSTITUTED PIPERAZINE DERIVATIVES - Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ArfGAP1, inhibition that counteracts the deleterious effects of mutations in, or increased expression of, the LRRK2 protein. | 2017-01-26 |
20170020867 | USE OF MASITINIB FOR THE TREATMENT OF CROHN'S DISEASE - A method for treating patients afflicted with Crohn's disease, wherein the patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient for treatment of Crohn's disease. | 2017-01-26 |
20170020868 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY - The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin. | 2017-01-26 |
20170020869 | Neuroprotective Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders - Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions. | 2017-01-26 |
20170020870 | SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS - Provided are methods of treating a variety of disorders of the skin with inhibitors of the epithelial sodium channel (ENaC). The inhibitors are represented by formula (I)-(IV): | 2017-01-26 |
20170020871 | Bromocriptine Formulations - The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes. | 2017-01-26 |
20170020872 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS - The invention relates to combinations comprising an HDAC inhibitor and a Her2 inhibitor for the treatment of breast cancer in a subject in need thereof. The invention also relates to combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof. Also provided herein are methods for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. Further provided are methods for inhibiting migration and/or invasion of a breast cancer cell in a subject by administering to the subject a HDAC6 specific inhibitor. | 2017-01-26 |
20170020873 | PHARMACEUTICAL COMPOSITIONS - A composition of an antitussive, a decongestant, or an antihistamine to treat upper respiratory and oral pharyngeal congestion and related symptoms in a patient. | 2017-01-26 |
20170020874 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS - There is provided a compound which is a histone deacetylase (HDAC) inhibitor, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in: (I) treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation; and/or (II) potentiating the degradation of fibrin deposits and preventing such deposits associated with pathological conditions or which may lead to such conditions, wherein the HDAC inhibitor, and the dose thereof, is as described in the description. There is also provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in improving or normalizing endogenous fibrinolysis impaired by local or systemic inflammation. | 2017-01-26 |
20170020875 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF - The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases. | 2017-01-26 |
20170020876 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF - The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases. | 2017-01-26 |
20170020877 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | 2017-01-26 |
20170020878 | COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR - A novel combination comprising a BTK inhibitor, for example: 1-[(3R)-3-[ | 2017-01-26 |
20170020879 | PYRAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS - This invention relates to pyrazolopyridyl compounds of the structural formula: | 2017-01-26 |
20170020880 | PHARMACEUTICAL COMPOSITIONS OF TRAMETINIB - The present disclosure relates to pharmaceutical compositions comprising trametinib. More specifically, the present disclosure relates to solid compositions comprising trametinib and processes for preparing the same. | 2017-01-26 |
20170020881 | NOVEL SELECTIVE PI3K DELTA INHIBITORS - The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them. | 2017-01-26 |
20170020882 | ANTIVIRAL FORMULATION - A topical antiviral composition comprising acyclovir, penciclovir and/or omaciclovir in a glucocorticoid-free pharmaceutical carrier comprising 15 to 25 weight % propylene glycol and 10 to 25 weight % isopropyl C | 2017-01-26 |
20170020883 | METHOD FOR PROMOTING WOUND HEALING BY ADMINISTERING A COMPOUND WHICH BINDS LDL-RECEPTOR-RELATED PROTEIN (LRP) LIGAND BINDING DOMAIN - The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands. | 2017-01-26 |
20170020884 | Methods for Treating Cancer Using Apilimod - The present invention relates to methods for treating cancer with apilimod and related compositions and methods. | 2017-01-26 |
20170020885 | Composition Comprising a Therapeutic Agent and a Respiratory Stimulant and Methods for the Use Thereof - The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure provides a pharmaceutical composition comprising a therapeutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory suppressants by combining a chemoreceptor respiratory stimulant with an opioid receptor agonist or other respiratory-depressing drug. The combination of the two chemical agents, that is, the therapeutic agent and the respiratory stimulant, may be herein described as the “drugs.” The present compositions may be used to treat acute and chronic pain, sleep apnea, and other conditions, leaving only non-lethal side effects. | 2017-01-26 |
20170020886 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS - The present invention relates to amido-substituted azole compounds of general formula (I), in which X | 2017-01-26 |
20170020887 | PREVENTIVE/THERAPEUTIC METHOD AND PREVENTIVE/THERAPEUTIC AGENT FOR COMPLICATIONS AFTER CATARACT SURGERY - The present invention provides a method for the prevention and treatment of complications after cataract surgery such as secondary cataract and anterior capsule contraction that occur after cataract operation. | 2017-01-26 |
20170020888 | Treatment of Impaired Cognitive Flexibility with TrkB Receptor Antagonists - The cognitive flexibility of a subject may be improved by administering a therapeutically effective amount of a TrkB receptor antagonist to the subject in need thereof. The TrkB receptor antagonist compound may be administered in a pharmaceutical dosage form. | 2017-01-26 |
20170020889 | DRUG THERAPY FOR PREVENTING OR TREATING GLAUCOMA - There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma. | 2017-01-26 |
20170020890 | PHARMACEUTICAL COMPOSITION COMPRISING FATTY ACID DERIVATIVE - An oral pharmaceutical composition comprising (a) a specific fatty acid derivative, (b) a specific sweetening agent and (c) a pharmaceutically acceptable oily vehicle, and an oily liquid formulation comprising thereof is provided. | 2017-01-26 |
20170020891 | USE OF DOPAMINE AND SEROTONIN RECEPTOR ANTAGONISTS FOR TREATMENT IN A SUBJECT WITH RETINAL DEGENERATION - Disclosed herein are methods of treating disorders of the retina (e.g., macular degeneration, retinitis pigmentosa, etc.) comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound (for example, an antipsychotic drug) that blocks or diminishes agonist-mediated responses upon binding to either dopamine D2-like receptors or serotonin 5-HT2 receptors. | 2017-01-26 |
20170020892 | USE OF NEGATIVE MODULATORS OF GABA RECEPTORS CONTAINING ALPHA5 SUBUNITS AS FAST ACTING ANTIDEPRESSANTS - Embodiments of the disclosure include methods and compositions related to treatment of one or more medical conditions with one or more negative modulators of GABA | 2017-01-26 |
20170020893 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select lipobalanced testosterone prodrugs and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a lipobalanced testosterone prodrugs and a pharmaceutically acceptable carrier. | 2017-01-26 |
20170020894 | BILE ACID RECEPTOR AGONISM FOR TREATING ADDICTION - Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agonizing bile acid receptors in the subject. For example, in some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a therapeutically effective amount of a bile acid receptor agonist. In some embodiments, the method comprises surgically diverting bile acids in the subject in a manner suitable to increase circulating bile acids in the subject. | 2017-01-26 |
20170020895 | Non-Surgical Method of Treatment for Cataract - The invention provides inhibitors of α-crystallin aggregation and methods of using α-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (T | 2017-01-26 |
20170020896 | TOPICAL NANODRUG FORMULATION - A formulation includes a nanostructured lipid carrier (NLC) matrix and spironolactone as an active ingredient loaded within the NLC matrix, forming a spironolactone-loaded NLC (SP-NLC) gel or lotion. | 2017-01-26 |
20170020897 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described. | 2017-01-26 |
20170020898 | TOPICAL PHARMACEUTICAL COMPOSITIONS - There is provided a topical pharmaceutical composition comprising the following components and percentages: ester of salicylic or nicotinic acid—10-20%; menthol—5-10%; lower alcohol—15-35%; water—10-20%; propylene glycol and/or pentane-1,5-diol—15-35%; hydrophilic pharmaceutically-acceptable non-volatile non-solvent for menthol—2-16%; and, optionally, up to 5% camphor, all percentages being by weight. Also provided is a topical pharmaceutical composition comprising a volatile phase and a non-volatile phase, the non-volatile phase comprising from 32-81% of the total composition by weight, and comprising the following non-volatile constituents, expressed as % weight of the non-volatile phase: ester of salicylic or nicotinic acid—14-48%; menthol—7-27%; propylene glycol and/or pentane-1,5-diol—25-67%; hydrophilic pharmaceutically-acceptable non-volatile non-solvent for menthol—3-35%, and a concentrate comprising the non-volatile components of this composition. The compositions are useful in the treatment or prevention of pain. | 2017-01-26 |
20170020899 | ADJUVANT THERAPY TO STANDARD OF CARE (SOC) DIURETIC TREATMENT - A therapeutic method for treating and/or preventing diseases and medical conditions typically treated by administering diuretic agents (eg congestive heart failure). The method may comprise, for example, administering to a subject a diuretic agent in combination with vessel dilator (VSDL) or a variant or modified peptide thereof. The administration of the diuretic agent may be a component of a standard of care (SOC) treatment. | 2017-01-26 |
20170020900 | METHODS FOR SCREENING ANTIMICROBIAL AND ANTIVIRAL COMPOUNDS AND USES THEREOF - The invention features compounds that have antibacterial activity, their use for the treatment of bacterial infections, screening methods that use whole animals or plant seedlings to identify compounds that inhibit a pathogen in the animal or plant, and screening methods to identify compounds that increase the lifespan of an organism. | 2017-01-26 |
20170020901 | TREATMENT OF CERVICAL CANCER WITH GOLD(I) COMPLEXES - Gold(I) complexes of formulae [Au{P(t-Bu) | 2017-01-26 |
20170020902 | Method for Improving Drug Treatments in Mammals - An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants. | 2017-01-26 |
20170020903 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE - Use of a derivative containing C-O-P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent. | 2017-01-26 |
20170020904 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2017-01-26 |
20170020905 | COMPOSITIONS AND METHODS FOR TREATING AN AGGREGATION DISEASE OR DISORDER - The present invention alleviates a sign or symptom of an aggregation disease or disorder by administering an aqueous formulation comprising trehalose. | 2017-01-26 |
20170020906 | METHODS FOR ENHANCING MUCOSAL INNATE IMMUNE RESPONSES TO AND/OR DETECTION OF PATHOGENS USING HUMAN MILK OLIGOSACCHARIDES - A method for enhancing an individual's mucosal innate immune response to pathogens is disclosed. The method includes a step of administering a nutritional composition to the individual. The nutritional composition includes about 0.05 to about 0.5 mg/mL 2′-fucosyllactose (2′-FL), about 0.05 to about 0.5 mg/mL lacto-N-neotetraose (LNnT), or a combination of both. Also disclosed is a method for enhancing an individual's mucosal innate immune detection of pathogens. The method includes a step of administering a nutritional composition to the individual. The nutritional composition includes a neutral human milk oligosaccharide. | 2017-01-26 |
20170020907 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. | 2017-01-26 |
20170020908 | CONTROL RELEASE OF FAT SOLUABLE ANTIOXIDANTS FROM AN ORAL FORMULATION AND METHOD - Oral formulation of particles made of an agglomeration of a plurality of seed granules or a single seed granule both surrounded by three layers and an outer gel coating. The seed granules are made of calcium carbonate with microscopic fissures. Disposed inside the fissures and in the interstitial spaces of the agglomerate seed granules are microscopic particles of alkali metal salts and other ions. Coating the agglomerate or single seed granules is an alkaline-resistant first layer made of microcrystalline cellulose and croscarmellose sodium that binds and protects the surrounding second layer. Surrounding the second layer is a third layer made of alkaline earth metal salt particles holding alkali metal hydroxide ions within a polysaccharide or polymer gel. Surrounding the third layer is at least one outer gel layer. The fourth and third layers dissolve in a low pH environment and release the fat soluble antioxidant and ions in the seed granule fissures. | 2017-01-26 |
20170020909 | METHODS OF TREATING GLAUCOMA USING AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS - Methods of reducing intraocular pressure in a mammal using AMPK activators, e.g., for treating glaucoma. | 2017-01-26 |
20170020910 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL - Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness. | 2017-01-26 |
20170020911 | ANTITHROMBIN-HEPARIN COMPOSITIONS AND METHODS - Compositions and methods for preventing thrombogenesis can include antithrombin and heparin. In one example, a conjugate of antithrombin and heparin where at least 50 wt % of the heparin is conjugated to antithrombin can be present. Furthermore, in one example, at least 98 wt % of the heparin in the composition has a molecular weight greater than 3,000 Daltons. | 2017-01-26 |
20170020912 | POLYMER MATRIX COMPOSITIONS COMPRISING A HIGH CONCENTRATION OF BIO-FERMENTED SODIUM HYALURONATE AND USES THEREOF - The present invention relates to stable polymer matrix compositions comprising high concentrations (from about 1.5% w/w to about 3.5% w/w) sodium hyaluronate obtained from a | 2017-01-26 |
20170020913 | PHARMACEUTICAL COMPOSITIONS WITH HYDRATING AND LUBRICATING ACTIVITY - The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and/or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa. | 2017-01-26 |
20170020914 | ANTIOXIDANT COMPOSITION - The present invention relates to an antioxidant composition comprising a combination of galatomannan and N-acetyl cysteine for its use in the treatment of a skin disease or condition resulting from reactive oxygen species production in the skin or involving reactive oxygen species production in the skin, to a hydrogel containing said combination as well as to dressing wounds comprising said hydrogel and its use in the healing of ulcers, wounds, burns and scalds. | 2017-01-26 |
20170020915 | SILICON-CONTAINING BIODEGRADABLE MATERIAL FOR ANTI-INFLAMMATORY THERAPY - A method for preventing and/or treating a disease associated with increased interleukin-1β and/or interleukin-6 and/or interleukin-8 activity and/or disease, in which a reduction in the activity of interleukin-1β and/or interleukin-6 and/or interleukin-8 is beneficial for healing includes utilizing a silicon-containing, biodegradable material containing a polyhydroxysilicic acid ethyl ester compound, with the proviso that wound defects including chronic diabetic-neuropathic ulcer, chronic leg ulcer, bedsores, secondary-healing infected wounds, non-irritating, primary-healing wounds, ablative lacerations and/or abrasions, are excluded from said disease that is prevented and/or treated with the silicon-containing, biodegradable material. | 2017-01-26 |
20170020916 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA - The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function. | 2017-01-26 |
20170020917 | PROCESS FOR THE IDENTIFICATION OF COMPOUNDS FOR TREATING CANCER - Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer. | 2017-01-26 |
20170020918 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION - Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions. | 2017-01-26 |
20170020919 | MICRO- AND NANO-QUANTITY SLEEP ENHANCING NUTRIENT COMPOSITION AND METHOD OF ENHANCING CENTRAL NERVOUS SYSTEM PROTEIN CLEARANCE USING SAME - The present invention relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present invention relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, activation of the glymphatic system to facilitate clearance of neuronal metabolites from the CSF and interstitial fluids in the brain. | 2017-01-26 |
20170020920 | HIGH-LOADING, CONTROLLED-RELEASE MAGNESIUM ORAL DOSAGE FORMS AND METHODS FOR MAKING AND USING SAME - Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. | 2017-01-26 |
20170020921 | Citrate-Rich Calcium-Magnesium Supplement and Uses Thereof - Disclosed is an effervescent preparation of calcium and magnesium with additional citric acid in a defined ratio. Also disclosed is the use of these compositions to raise cardioprotective citrate and magnesium in serum to help prevent heart attacks from calcium supplements, and to provide bioavailable calcium and magnesium to prevent osteoporosis-related fractures and low blood magnesium from the use of proton pump inhibitors. | 2017-01-26 |
20170020922 | GENE EDITING FOR IMMUNOLOGICAL DESTRUCTION OF NEOPLASIA - Disclosed are methods, protocols, and compositions of matter useful for induction and/or propagation of antitumor immune responses through gene editing of immunocytes. Stimulation of antitumor adaptive immunity is achieved through gene editing of autologous or allogeneic lymphocytes in a manner to derepress neoplasia induced suppression. The method can include targets of gene editing disclosed in the current invention include the E3 ubiquitin ligase Cbl-b, CTLA-4, PD-1, TIM-3, killer inhibitory receptor (KIR) and LAG-3. | 2017-01-26 |
20170020923 | PLATELET RICH PLASMA FORMULATIONS - Compositions for platelet rich plasma (PRP) and neutrophil-depleted PRP are provided. Methods for treating ischemia damaged tissues by delivering a PRP composition, in some embodiments a neutrophil-depleted PRP composition to the damaged tissue are provided. In some variations, the compositions may be useful to treat ischemic heart disease and repair damaged cardiovascular tissue following acute myocardial infarction including congestive heart failure. In some variations, the compositions may be useful to reduce cardiac apoptosis after a heart attack. | 2017-01-26 |
20170020924 | MESENCHYMAL STEM CELL, METHOD FOR CLONOGENIC EXPANSION THEREOF, METHOD FOR ISOLATING THEREOF, AND USE THEREOF - A mesenchymal stem cell is provided. The mesenchymal stem cell that expresses an insulin-like growth factor 1 receptor have been cultured in media containing human cord blood serum and isolated, such that an insulin-like growth factor 1 receptor expression is enhanced in the isolated mesenchymal stem cells. | 2017-01-26 |
20170020925 | METHODS FOR MONITORING CELLULAR STATES AND FOR IMMORTALIZING MESENCHYMAL STEM CELL - We describe a method of monitoring the state of a cell, the method comprising establishing, for a selected microRNA (miRNA) species secreted by the cell, a ratio of: (a) a precursor form of the miRNA species (pre-miRNA); to (b) a mature form of the miRNA species (mature miRNA); in which the pre- to mature miRNA ratio so established is indicative of the state of the cell. We also describe a method comprising the steps of: (a) providing a mesenchymal stem cell (MSC); and (b) introducing an oncogene into the mesenchymal stem cell to thereby transform it; in which the transformed mesenchymal stem cell does not secrete a gene product of the oncogene into a medium in which it is grown. | 2017-01-26 |
20170020926 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION - Provided are cells containing exogenous antigen and uses thereof. | 2017-01-26 |
20170020927 | ACELLULAR BIOLOGIC COMPOSITION AND METHOD OF MANUFACTURE - A biological composition has a mixture of mechanically selected allogeneic biologic material derived from placental tissue. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function. | 2017-01-26 |
20170020928 | Flowable Concentrated Phospholipid Krill Oil Composition - The present invention is related to methods of making crustacean oil compositions. In particular, the crustacean oil compositions are krill oil compositions. In some embodiments, the krill oil compositions are concentrated in phospholipids. These concentrated phospholipid krill oil compositions have a sufficient flowability to permit successful encapsulation at phospholipid concentrations that is currently unattainable in the art. Such phospholipid krill oil compositions are capable of encapsulation even though they may have a phospholipid concentration ranging between approximately 60%-99% and a viscosity ranging between 100,000-3,000,000 cP. Such concentrated phospholipid krill oil compositions may be created using a small molecule organic solvent/water extraction mixture and/or sub-critical or super-critical fluid extraction at low temperatures followed by a drying process to remove water and organic solvent (e.g., for example, ethanol). | 2017-01-26 |
20170020929 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY RELATED DISEASES OR CONDITIONS USING PEDIOCOCCUS ACIDILACTICI PROBIOTICS - The present invention provides a method of treating a disease or condition characterized by inflammation in a subject in need thereof, comprising administering to the subject an effective amount of a | 2017-01-26 |
20170020930 | PREVENTION OF PREGNANCY COMPLICATIONS BY PROBIOTIC ADMINISTRATION - Methods for the treatment of pregnancy complications through immune modulation are disclosed. Also disclosed are probiotic compositions capable of inducing an anti-inflammatory immune response in a subject. The probiotic composition may include one or more of | 2017-01-26 |
20170020931 | USE OF BACTERIA, BACTERIAL PRODUCTS, AND OTHER IMMUNOREGULATORY ENTITIES IN COMBINATION WITH ANTI-CTLA-4 AND/OR ANTI-PD-1 ANTIBODIES TO TREAT SOLID TUMOR MALIGNANCIES - The presently disclosed subject matter provides methods and kits for treating solid tumors in a subject by using a combination of anti-CTLA-4 and/or anti-PD-1 antibodies with at least one member of the group consisting of a bacterium, bacterial product, and an immunoregulatory entity. In particular embodiments, the bacteria are toxin-depleted, anaerobic bacteria, such as | 2017-01-26 |
20170020932 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS - The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions. | 2017-01-26 |
20170020933 | NOVEL LACTOBACILLUS PLANTARUM AND COMPOSITION COMPRISING SAME - The present invention provides | 2017-01-26 |
20170020934 | LACTOBACILLUS CRISPATUS AND APPLICATION THEREOF - The present invention discloses | 2017-01-26 |
20170020935 | COMPOSITIONS AND METHODS FOR INHIBITING PATHOGENIC GROWTH - The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of | 2017-01-26 |
20170020936 | Production and Use of Bacterial Histamine - A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions. | 2017-01-26 |
20170020937 | TREATMENT OF TOPICAL AND SYSTEMIC BACTERIAL INFECTIONS - Bacteriophage covalently attached to a carrier particle with an average diameter of from 0.1 microns to 15 microns, are used in topical treatment of bacterial infection. Bacteriophage covalently attached to a carrier particle of average diameter 7 microns or less are used in systemic treatment of bacterial infection. A plurality of bacteriophages lytic against different bacterial strains gives wide antibacterial activity. A combination therapy comprises administration of antibiotic and bacteriophage covalently attached to a carrier particle. | 2017-01-26 |
20170020938 | Oncolytic Vaccinia Virus - The present invention relates to an oncolytic vaccinia virus and virus vectors for use in cancer therapy where in the virus comprises at least three vaccinia virus promoters which are positioned in the same orientation. | 2017-01-26 |
20170020939 | IMMUNE BALANCE REGULATOR - The present invention provides a novel immune balance regulator that regulates an immune balance in a living body. The immune balance regulator contains a | 2017-01-26 |
20170020940 | METHODS FOR INHIBITING HIV-1 ACTIVITY BY INHIBITORY MECHANISMS OF EXTRACTS OF GUAIACUM OFFICINALE L. (ZYGOPHYLLACEAE) - A therapeutic phenolic extract derived from plant biomass, and more specifically the indigenous Jamaican plant | 2017-01-26 |
20170020941 | MEDICATION DISPENSING SYSTEM - A method for treating cancer is disclosed by boiling blended | 2017-01-26 |
20170020942 | MEDICATION DISPENSING SYSTEM - A method for treating cancer is disclosed by boiling blended cannabis material with oil and collecting oil infused with cannabis; targeting cancerous cells in a body; and injecting the oil infused with cannabis into the body portion with cancerous cells. | 2017-01-26 |
20170020943 | METHOD FOR INCREASING CANNABINOL CONTENT IN A LIPID-BASED EXTRACT OF CANNABIS - A method for modifying cannabinol (CBN) to trans-Δ9-tetrahydrocannabinol (THC) content in a lipid-based extract of | 2017-01-26 |
20170020944 | SYSTEMS AND METHODS FOR CANNABINOID AND TERPENE EXTRACTION AND PURIFICATION - A method for preparing a purified | 2017-01-26 |
20170020945 | FOOD AND BEVERAGE COMPOSITIONS INFUSED WITH LIPOPHILIC ACTIVE AGENTS AND METHODS OF USE THEREOF - Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents. | 2017-01-26 |
20170020946 | ANALGESIC COMPOSITIONS AND METHODS OF USE - The invention relates to the fields of pharmacology and medicine, and provides anesthetic compositions and methods for the treatment of pain using compositions comprising Tea tree oil and one or more additional agent. The invention relates to analgesic compositions for the treatment of pain associated with a variety of disorders or conditions, particularly oral or dental disorders or conditions such as alveolar osteitis or dental caries. | 2017-01-26 |
20170020947 | Methods of Feeding Animals Liquid Feed with Soluble Fiber and Sugar Alcohol - An animal feed such as a milk replacer includes a soluble fiber and a sugar alcohol. The milk replacer enhances weight gain, starter intake and reduces weaning time. The method of feeding the animal includes feeding a mixture of a soluble fiber and sugar alcohol. The animal feed may be used as a method of weaning young ruminants such as calves. | 2017-01-26 |
20170020948 | PHYTOCOMPLEXES EXHIBITING MULTIPLE, SYNERGISTIC ANTIOXIDANT ACTIVITIES USEFUL IN FOODS, DIETARY SUPPLEMENTS, COSMETICS AND PHARMACEUTICAL PREPARATIONS - Compositions comprising apple, grape, green tea, and olive extracts are presented herein. This synergistic formulations apple, grape, green tea, and olive extract are in amounts that provide a greater antioxidant activity or protein kinase modulating activity than provided by an equivalent amount of any one extract or a sum of the extracts. Further presented are methods of regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. Also presented are methods of making an activity enhancing composition for regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. | 2017-01-26 |
20170020949 | COMPOSITIONS COMPRISING KAKADU PLUM EXTRACT OR ACAI BERRY EXTRACT - A method of reducing TNF-α production in human epidermal keratinocytes, the method comprising topically applying to skin in need thereof a composition comprising an effective amount of a liquid kakadu plum extract comprising kakadu plum fruit, alcohol, and butylene glycol to reduce TNF-α production in human epidermal keratinocytes of the skin, and an effective amount of a liquid acai berry extract comprising acai berry fruit, water, and alcohol to reduce TNF-α production in human epidermal keratinocytes of the skin. | 2017-01-26 |
20170020950 | METHODS FOR MODULATING KINASES - A method for modulating a kinase by administering to a subject a nutritional composition comprising extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof. A modulated kinase may be a kinase that regulates inflammatory signaling, immune tolerance, metabolic signaling, cell cycle and growth factor signaling. The nutritional composition may dose-dependently inhibit a range of serine, threonine and tyrosine kinases. | 2017-01-26 |
20170020951 | NEUROPEPTIDE ANALOGS, COMPOSITIONS, AND METHODS FOR TREATING PAIN - Neuropeptide analogs and compositions including neuropeptide analogs are described herein. Also provided are methods of producing and using the neuropeptide analogs and compositions including one or more neuropeptide analogs. | 2017-01-26 |
20170020952 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND MOOD DISORDERS - Methods of treating a central nervous system (CNS) disorder or mood disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising a melanocortin 5 receptor (MC5R) peptide ligand in a pharmaceutically acceptable carrier is administered to the subject. The MC5R peptide ligand is a selective MC5R antagonist, in which administration thereof to the subject can treat the CNS disorder or mood disorder with clinical improvement observed in a relatively short time. | 2017-01-26 |
20170020953 | METHODS FOR THE TREATMENT OF DEPRESSION AND ANXIETY - Methods of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising Ac-Nle | 2017-01-26 |
20170020954 | Therapeutic Methods Using Cyclosporine Components - Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis. | 2017-01-26 |
20170020955 | ANTHELMINTIC COMBINATIONS AND METHODS OF USE THEREOF - The present invention relates to a veterinary composition comprising an effective amount of at least one cyclic depsipeptide and at least one macrocyclic lactone; and a pharmaceutically acceptable carrier, for the treatment or prophylaxis of parasitic infection in a mammal wherein the parasite shows resistance to treatment or prophylaxis with the macrocyclic lactone alone. | 2017-01-26 |
20170020956 | Peptides Having Anti-Inflammatory Properties - Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals. | 2017-01-26 |
20170020957 | METHODS OF REDUCING THE NEED FOR SURGERY IN PATIENTS SUFFERING FROM BENIGN PROSTATIC HYPERPLASIA - The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof. Carrying out the method unexpectedly reduces the need for subsequent invasive surgical intervention. | 2017-01-26 |
20170020958 | STEM CELLS FOR ANTI-ANGIOGENIC THERAPY IN AGE-RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, CORNEAL VASCULARISATION AND CANCER - The present invention relates to production of a stem cell expressing an anti-angiogenic protein. The stem cells are used to inhibit angiogenesis for treatment of macular degeneration, corneal vascularisation, cancer and diabetic retinopathy. | 2017-01-26 |
20170020959 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISORDERS - The present invention provides a method for the prevention or treatment of a neurodegenerative disorder in a subject, comprising administering to the subject a therapeutically effective amount of an agent that increases Nix-mediated mitophagy in a cell. Also provided is a method for identifying a compound useful for the prevention or treatment of a neurodegenerative disorder in a subject. | 2017-01-26 |
20170020960 | LIQUID FORMULATIONS OF TUMOR NECROSIS FACTOR-BINDING PROTEINS - The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent. | 2017-01-26 |
20170020961 | Methods for Treating Peripheral Nerve Damage - VEGF-B, as well as a combination of VEGF-B and VEGF-A, mediates peripheral nerve repair. Methods to treat damage to the peripheral nervous system are described. | 2017-01-26 |
20170020962 | INTERLEUKIN-2 FOR TREATING FOOD ALLERGY - The present invention relates to the use of interleukin-2 (IL-2) for treating a food allergy, either by inducing non-specific tolerance against food allergens, or in a desensitization protocol, in combination with a food allergen. | 2017-01-26 |